The therapy aims to provide systemic delivery of oligonucleotides to the brain for neurological treatment.
Live Poll
Should medical research prioritize new delivery methods for brain-related drug treatments?
October 6, 2026
FDA Accepted New Drug Application for InfigratinibThe drug targets children with achondroplasia and has been granted Priority Review for a 2027 decision.
October 6, 2026
QIAGEN Introduced New AI Bioinformatics ToolsThe company launched AI capabilities for its research software and platforms to automate complex drug discovery workflows.
October 6, 2026
Biotech Firms Have Used AI to Replicate Rare ScentsCompanies are using artificial intelligence to recreate endangered plant aromas and reduce environmental harvest pressure.
October 6, 2026
ViiV Healthcare Met Primary Endpoint in HIV StudyThe Phase 3b Crown trial showed that Cabenuva successfully achieves viral suppression in patients with detectable HIV-1.
October 6, 2026
New World Medical Received EU Certification for Glaucoma ToolsThe company has secured Medical Device Regulation certification for three of its primary ophthalmic products.
October 6, 2026
PacBio and TychoBio Partnered for RNA Therapy ResearchThe companies have joined forces to use high-fidelity sequencing to train artificial intelligence models for rare diseases.
October 6, 2026
ESMT Report Identified Structural Biotech FailuresA new study outlines urgent reform needs to prevent European biotechnology talent and capital flight to the US.
October 6, 2026
OKYO Pharma Initiated Phase 3 Urcosimod TrialThe company enrolled its first patients in a study targeting neuropathic corneal pain.
October 6, 2026
Sensible Biotechnologies Secured $47 Million FinancingThe biotech firm raised new capital to scale its mRNA design platform and clinical-grade manufacturing capabilities.
October 6, 2026
Forbion Has Raised €2.3 Billion for Biotech FundsThe firm successfully secured capital to support the growth of approximately 30 new companies in the sector.
